Startups Directory

Nsilica Simulation Technologies is a technology-driven startup and spin-off from the University of Vigo, founded in 2024 with a clear mission: to democratize lab-accuracy biomechanics. To achieve this, we developed nMotion, an AI-powered motion capture and biomechanical analysis system based on proprietary IMU hardware and software fully designed and developed in-house. nMotion combines wearable sensors with a cloud-based, user-friendly web application that allows professionals to easily capture, visualize, and analyze human movement. Our solution is designed for physiotherapy, rehabilitation, and sports performance, bringing laboratory-grade biomechanical insights to real-world environments. nMotion is currently being validated with early adopters across these sectors, while we progress through CE certification and prepare for our go-to-market phase.

Nsilica Simulation Technologies is a technology-driven startup and spin-off from the University of Vigo, founded in 2024 with a clear mission: to democratize lab-accuracy biomechanics. To achieve this, we developed nMotion, an AI-powered motion capture and biomechanical analysis system based on proprietary IMU hardware and software fully designed and developed in-house. nMotion combines wearable sensors with a cloud-based, user-friendly web application that allows professionals to easily capture, visualize, and analyze human movement. Our solution is designed for physiotherapy, rehabilitation, and sports performance, bringing laboratory-grade biomechanical insights to real-world environments. nMotion is currently being validated with early adopters across these sectors, while we progress through CE certification and prepare for our go-to-market phase.

Our technology contributes to society by making objective biomechanical analysis accessible beyond specialized laboratories, enabling professionals to base their decisions on quantitative data rather than subjective observation. In healthcare and rehabilitation, nMotion supports earlier detection of movement alterations, more personalized treatment planning, and continuous monitoring of patient progress. This is particularly relevant in the context of neurological and neurodegenerative diseases, where subtle changes in movement patterns over time can provide valuable information for assessing disease progression and treatment effectiveness. By enabling regular, objective movement assessment in real-world environments, nMotion can help clinicians track functional decline or improvement more precisely, supporting better-informed clinical decisions without adding complexity or burden to patients. More broadly, nMotion promotes a shift toward data-driven care in human movement, improving quality of life, reducing long-term healthcare costs, and democratizing access to biomechanical technologies that were previously limited to specialized centers.

We are raising €320,000 in this round, with €160,000 allocated to investors. This investment will enable us to finalize CE certification, complete product validation with early adopters, strengthen our hardware and software platform, and execute our initial go-to-market strategy. The round is structured to take nMotion from late validation to early commercialization.

€320,000

A company dedicated to R&D.

A company dedicated to R&D.

Enhanced energy production by optimization and life's extension of PV panels.

One million Euros

200 000 euros

We’re building certification-less space access giving 10x lower project cost & time. Our zero-gravity platform opens-up research in space for people that could never go before. Our first mission is sold out, with experiments in biotech, pharma, ISRU, and quantum computing.

We’re building certification-less space access giving 10x lower project cost & time. Our zero-gravity platform opens-up research in space for people that could never go before. Our first mission is sold out, with experiments in biotech, pharma, ISRU, and quantum computing.

By eliminating sedimentation, buoyancy, and convection, our platform enables breakthrough research for Earth-based industries, including biotech, pharmaceuticals, material science, and fundamental physics. We provide a unique environment to save millions of lives through advanced disease modelling, biofabrication & stem cell growth, and protein crystallisation. Also, by producing semiconductors and nanostructures in space, we can create essentially "perfect" materials that aren't possible on Earth. These advance our daily lives by making renewable energy more efficient, enabling faster connectivity with new 6G networks, and providing the massive processing power needed for next-generation AI.

0.5 M EUR

1.5 M EUR

WAPTEL (Wave and Particle Engineering Solutions) is a private fabless technology company based in Madrid that specializes in the design and development of high-tech photonic and electronic solutions, products, and services. Its capabilities span from concept and physical simulation of structures and devices to final system characterization, including manufacturing process definition and integrated circuit or structure design. The company conducts R&D in semiconductor technologies (especially III-V, lithium niobate and silicon), photonics, quantum devices, and wireless optical communications, and it possesses in-house prototyping facilities for advanced device development. WAPTEL’s work applies across consumer information and communication technologies as well as specialized areas such as aerospace, health, energy, security, and defense.

WAPTEL (Wave and Particle Engineering Solutions) is a private fabless technology company based in Madrid that specializes in the design and development of high-tech photonic and electronic solutions, products, and services. Its capabilities span from concept and physical simulation of structures and devices to final system characterization, including manufacturing process definition and integrated circuit or structure design. The company conducts R&D in semiconductor technologies (especially III-V, lithium niobate and silicon), photonics, quantum devices, and wireless optical communications, and it possesses in-house prototyping facilities for advanced device development. WAPTEL’s work applies across consumer information and communication technologies as well as specialized areas such as aerospace, health, energy, security, and defense.

This technology can improve high-speed optical communications while reducing energy consumption, enabling more efficient networks and data systems.

1 M€

The total size of the investment round is planned to be approximately 1M€.

Development of a new instrument to perform visual refraction more quickly and accurately than the conventional method.

Development of a new instrument to perform visual refraction more quickly and accurately than the conventional method.

A paradigm shift in an evaluation method that has remained unchanged for over 200 years.

€350,000

€500,000

Repertor.IO is an innovative startup and academic spin-off of the Universities of Turin and Padua focused on making patient preferences usable in healthcare decision-making. Although Patient Preference Information is increasingly required by regulators such as EMA and FDA, it is still rarely used in practice due to fragmented evidence, methodological complexity, and time-consuming analyses. To address this gap we created Repertorio, the first and currently the only end-to-end platform specifically designed to overcome these barriers. By using AI-based methods to extract, structure, and synthesize patient preference data, and by performing advanced quantitative analyses, the platform delivers fast, reproducible, and decision-ready outputs. Repertorio enables pharma companies, regulators, HTA bodies, and researchers to systematically integrate the patient perspective across the medical product lifecycle, supporting the transition toward truly patient-centred care.

Repertor.IO is an innovative startup and academic spin-off of the Universities of Turin and Padua focused on making patient preferences usable in healthcare decision-making. Although Patient Preference Information is increasingly required by regulators such as EMA and FDA, it is still rarely used in practice due to fragmented evidence, methodological complexity, and time-consuming analyses. To address this gap we created Repertorio, the first and currently the only end-to-end platform specifically designed to overcome these barriers. By using AI-based methods to extract, structure, and synthesize patient preference data, and by performing advanced quantitative analyses, the platform delivers fast, reproducible, and decision-ready outputs. Repertorio enables pharma companies, regulators, HTA bodies, and researchers to systematically integrate the patient perspective across the medical product lifecycle, supporting the transition toward truly patient-centred care.

-Patients Repertorio helps ensure that new medical products and therapies reflect what patients truly value. Patient Preference Studies often show that patients and clinicians prioritize benefits, risks, and treatment burden differently, especially for innovative or high-risk therapies. By making patient preference evidence usable in practice, Repertorui supports more acceptable treatments, better shared decision-making, and improved adherence. -Regulators and public decision-makers EMA and FDA increasingly encourage the use of Patient Preference Information to support benefit–risk assessments, as demonstrated by recent regulatory decisions. At the same time, Health Technology Assessment (HTA) bodies and public payers are looking for robust patient-centred evidence to inform reimbursement, pricing, and coverage decisions. Repertorio enables transparent, reproducible, and patient-centred evidence to be systematically integrated into regulatory, HTA, and payer processes, improving the quality, consistency, and legitimacy of decision-making across the healthcare system. -Industry For pharmaceutical and life science companies, Repertorio enables more informed and patient-aligned development of medical products by translating patient preferences into actionable evidence. Integrating Patient Preference Information has been shown to increase expected net present value (≈ USD 35–70 million per project) and accelerate time to market ( by up to 2.5 years). Repertorio also helps reduce development costs by enabling a more efficient use and synthesis of existing patient preference evidence, avoiding redundant analyses and improving decision-making efficiency. Beyond efficiency gains, the platform supports the identification and profiling of patient segments with different preference patterns, informing product design, positioning, and market access strategies that better reflect real patient needs.

€500.000 for 2 years

€500000

GastroIntel is an AI based assistant designed to help professionals prepare for fairs and B2B events. It provides key information about companies and contacts, and helps start smarter conversations and find business opportunities more easily

GastroIntel is an AI based assistant designed to help professionals prepare for fairs and B2B events. It provides key information about companies and contacts, and helps start smarter conversations and find business opportunities more easily

GastroIntel helps professionals work more efficiently, reduce wasted time at events, and create better business connections. This leads to more meaningful collaboration and smarter use of knowledge and technology.

We are not raising investment at this stage

Not applicable. No investment round planned yet

Smart Scoliosis Developments SL is an innovative, technology-based startup dedicated to developing advanced solutions for the treatment of scoliosis, specifically adolescent idiopathic scoliosis (AIS).

Smart Scoliosis Developments SL is an innovative, technology-based startup dedicated to developing advanced solutions for the treatment of scoliosis, specifically adolescent idiopathic scoliosis (AIS).

Improving Current Outcomes in the Treatment of Adolescent Idiopathic Scoliosis

600.000€

1.200.000€

We are a technology startup focused on improving safety and efficiency in logistics through IoT and AI. Our core product, SiChock, is a patented smart wheel chock that prevents accidents at loading docks by automatically ensuring vehicle immobilization before loading or unloading operations can begin. Using IoT connectivity and data analytics, SiChock transforms a traditional safety element into an intelligent system that enhances workplace safety while generating valuable operational data for logistics and industrial facilities

We are a technology startup focused on improving safety and efficiency in logistics through IoT and AI. Our core product, SiChock, is a patented smart wheel chock that prevents accidents at loading docks by automatically ensuring vehicle immobilization before loading or unloading operations can begin. Using IoT connectivity and data analytics, SiChock transforms a traditional safety element into an intelligent system that enhances workplace safety while generating valuable operational data for logistics and industrial facilities

Our technology has a positive impact on society by making logistics and industrial workplaces safer, more efficient and more sustainable. By preventing accidents at loading docks, SiChock helps reduce injuries, fatalities and associated social and economic costs, improving workers’ health and well-being. At the same time, the data generated by the system enables companies to optimize logistics processes, reduce inefficiencies and improve productivity, contributing to more resilient and responsible supply chains. By combining safety with digitalization through IoT and data analytics, SiChock supports the transition toward smarter, safer and more sustainable industrial operations.

€430.000

€500.000

We are developing cutting-edge AI technology that enable industrial robots to autonomously perform waste‑sorting operations, significantly increasing throughput, operational efficiency, and worker safety in a critical link in the circular‑economy value chain.

We are developing cutting-edge AI technology that enable industrial robots to autonomously perform waste‑sorting operations, significantly increasing throughput, operational efficiency, and worker safety in a critical link in the circular‑economy value chain.

Our technology will improve society by making waste‑sorting safer, more efficient, and more sustainable. By automating the most repetitive and hazardous tasks, we reduce workers’ exposure to unsafe conditions and allow them to focus on higher‑value activities. At the same time, greater sorting accuracy increases the recovery of secondary raw materials, strengthening the circular economy and reducing the amount of waste sent to landfills or incineration.

1.200.000,00 €

300.000,00 €

We are a deep technology research laboratory that develops advanced algorithms for solving complex problems, demonstrating the solution using virtual reality and mixed reality.

We are a deep technology research laboratory that develops advanced algorithms for solving complex problems, demonstrating the solution using virtual reality and mixed reality.

Prevention in the diagnosis of heart disease. Savings for the National Health System of hundreds of millions of euros in cardiac mapping and navigation.

5 millions of euros

10 millions of euros

Juventas 4Life is dedicated to "delivering health to people through foods." We do research and develop new forms of food and supplements containing probiotics. Our probiotics do not require refrigeration to maintain their functionality and resist most industrial food manufacturing processes. They are supported by dozens of scientific studies, including clinical trials in humans. These properties allow us to develop a wide range of foods and beverages to reach the majority of the population (regardless of age) to strengthen people's overall health and well-being through the gut-microbiota-brain axis.

Juventas 4Life is dedicated to "delivering health to people through foods." We do research and develop new forms of food and supplements containing probiotics. Our probiotics do not require refrigeration to maintain their functionality and resist most industrial food manufacturing processes. They are supported by dozens of scientific studies, including clinical trials in humans. These properties allow us to develop a wide range of foods and beverages to reach the majority of the population (regardless of age) to strengthen people's overall health and well-being through the gut-microbiota-brain axis.

The impact will be to improve people's health and quality of life (healthspan), giving them the possibility of living more fully without getting sick (or getting sick less often). Precisely, our technology consists of offering different types of foods, drinks and supplements to people so that they have a wide and accessible range of options (to suit each person's taste and economic capacity) to strengthen their health and thus prevent the development of any type of disease.

No for the moment

No for the moment

Water treatment and water reuse using passive filtration concept.

Water treatment and water reuse using passive filtration concept.

Medium impact

400k€

1M€

At Wavefront we are developing the next generation of stain-free, quantitative live-cell imaging solutions. Our computational microscope uses a patented technology that protects cell integrity unlocking unique cellular information. Wavefront is on a mission to develop an imaging technology that will go way beyond being just a tool for researchers. Our vision is to use our proprietary technology to build robust new clinical diagnostics systems that can analyze patient samples anywhere, faster and at a fraction of current costs.

At Wavefront we are developing the next generation of stain-free, quantitative live-cell imaging solutions. Our computational microscope uses a patented technology that protects cell integrity unlocking unique cellular information. Wavefront is on a mission to develop an imaging technology that will go way beyond being just a tool for researchers. Our vision is to use our proprietary technology to build robust new clinical diagnostics systems that can analyze patient samples anywhere, faster and at a fraction of current costs.

Wavefront’s vision is to disrupt biomedical sciences and diagnostics by innovating cell imaging for a healthier world. Our technology has the potential to improve and automate medical diagnostics and other areas of biomedical sciences impacting positively on better and more affordable healthcare. In countries with a shortage of pathologists our solutions will provide a platform for remote diagnostics.

300.000€

300.000€

Biotech comany with a delivery system to help drugs reach the brain. First product in the field of pediatric brain tumors.

Biotech comany with a delivery system to help drugs reach the brain. First product in the field of pediatric brain tumors.

1 every 4 of us suffer from a brain disease during our life.

10M€

10M€